Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II triple combination pancreatic cancer trial of BL-8040, KEYTRUDA and chemotherapy

Trial Profile

A phase II triple combination pancreatic cancer trial of BL-8040, KEYTRUDA and chemotherapy

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Antineoplastics (Primary) ; BL 8040 (Primary) ; Pembrolizumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Nov 2018 New trial record
    • 08 Nov 2018 According to a BioLineRx media release, the company expects to initiate this trial by the end of 2018, with top-line data anticipated toward the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top